Maze Therapeutics (MAZE) Depreciation & Amortization (CF) (2024 - 2026)
Maze Therapeutics (MAZE) posted Depreciation & Amortization (CF) of $444000.0 for Q1 2026, down 10.48% sequentially from $496000.0 in Q4 2025, and down 35.09% YoY from $684000.0 in Q1 2025.
Maze Therapeutics (MAZE) Depreciation & Amortization (CF) (2024 - 2026) Analysis & Trends
Maze Therapeutics has reported Depreciation & Amortization (CF) for 3 years, with the latest figure at $444000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 35.09% year-over-year to $444000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (down 28.74% YoY) and the FY2025 annual result came in at $2.4 million, down 27.21% from the prior year.
- Depreciation & Amortization (CF) fell to $444000.0 in Q1 2026 per MAZE's latest filing, from $496000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $950000.0 in Q1 2024 and troughed at $444000.0 in Q1 2026.
- A 3-year average of $682333.3 and a median of $684000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2025 and 2026: Depreciation & Amortization (CF) slipped 24.0% in 2025, then plunged 35.09% in 2026.
- Over 3 years, Depreciation & Amortization (CF) stood at $705000.0 in 2024, then fell by 29.65% to $496000.0 in 2025, then retreated by 10.48% to $444000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $444000.0, $496000.0, and $571000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Maze Therapeutics | 1.51 Bn | 1.51 Bn | - | 391,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 391,000.00 |
| Jun 30, 2026 | 391,000.00 |
| Mar 31, 2026 | 444,000.00 |
| Mar 31, 2026 | 444,000.00 |
| Dec 31, 2025 | 496,000.00 |
| Dec 31, 2025 | 496,000.00 |
| Sep 30, 2025 | 571,000.00 |
| Sep 30, 2025 | 571,000.00 |
| Jun 30, 2025 | 649,000.00 |
| Jun 30, 2025 | 649,000.00 |
| Mar 31, 2025 | 684,000.00 |
| Mar 31, 2025 | 684,000.00 |
| Dec 31, 2024 | 705,000.00 |
| Dec 31, 2024 | 705,000.00 |
| Sep 30, 2024 | 788,000.00 |
| Sep 30, 2024 | 788,000.00 |
| Jun 30, 2024 | 854,000.00 |
| Jun 30, 2024 | 854,000.00 |
| Mar 31, 2024 | 950,000.00 |
| Mar 31, 2024 | 950,000.00 |